These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 28381268)

  • 1. The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis.
    Wang J; Pan Y; Shen J; Xu Y
    Ann Clin Microbiol Antimicrob; 2017 Apr; 16(1):24. PubMed ID: 28381268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis.
    Tasina E; Haidich AB; Kokkali S; Arvanitidou M
    Lancet Infect Dis; 2011 Nov; 11(11):834-44. PubMed ID: 21784708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review and Meta-Analysis.
    Ni W; Han Y; Liu J; Wei C; Zhao J; Cui J; Wang R; Liu Y
    Medicine (Baltimore); 2016 Mar; 95(11):e3126. PubMed ID: 26986165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence.
    Falagas ME; Lourida P; Poulikakos P; Rafailidis PI; Tansarli GS
    Antimicrob Agents Chemother; 2014; 58(2):654-63. PubMed ID: 24080646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis.
    Ni W; Han Y; Zhao J; Wei C; Cui J; Wang R; Liu Y
    Int J Antimicrob Agents; 2016 Feb; 47(2):107-16. PubMed ID: 26742726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A retrospective cohort study.
    Geng TT; Xu X; Huang M
    Medicine (Baltimore); 2018 Feb; 97(8):e9961. PubMed ID: 29465589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis.
    Kengkla K; Kongpakwattana K; Saokaew S; Apisarnthanarak A; Chaiyakunapruk N
    J Antimicrob Chemother; 2018 Jan; 73(1):22-32. PubMed ID: 29069421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis.
    Zha L; Pan L; Guo J; French N; Villanueva EV; Tefsen B
    Adv Ther; 2020 Mar; 37(3):1049-1064. PubMed ID: 32006240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease.
    Cai Y; Wang R; Liang B; Bai N; Liu Y
    Antimicrob Agents Chemother; 2011 Mar; 55(3):1162-72. PubMed ID: 21173186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections.
    Neuner EA; Yeh JY; Hall GS; Sekeres J; Endimiani A; Bonomo RA; Shrestha NK; Fraser TG; van Duin D
    Diagn Microbiol Infect Dis; 2011 Apr; 69(4):357-62. PubMed ID: 21396529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution.
    Chemaly RF; Hanmod SS; Jiang Y; Rathod DB; Mulanovich V; Adachi JA; Rolston KV; Raad II; Hachem RY
    Medicine (Baltimore); 2009 Jul; 88(4):211-220. PubMed ID: 19593226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tigecycline: a systematic review and meta-analysis.
    Yahav D; Lador A; Paul M; Leibovici L
    J Antimicrob Chemother; 2011 Sep; 66(9):1963-71. PubMed ID: 21685488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of tigecycline monotherapy versus combination therapy for the treatment of hospital-acquired pneumonia (HAP): a meta-analysis of cohort studies.
    Bai XR; Liu JM; Jiang DC; Yan SY
    J Chemother; 2018 May; 30(3):172-178. PubMed ID: 29405898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Tigecycline for Patients with Hospital-Acquired Pneumonia.
    Xu L; Wang YL; Du S; Chen L; Long LH; Wu Y
    Chemotherapy; 2016; 61(6):323-30. PubMed ID: 27144279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens.
    Poulakou G; Kontopidou FV; Paramythiotou E; Kompoti M; Katsiari M; Mainas E; Nicolaou C; Yphantis D; Antoniadou A; Trikka-Graphakos E; Roussou Z; Clouva P; Maguina N; Kanellakopoulou K; Armaganidis A; Giamarellou H
    J Infect; 2009 Apr; 58(4):273-84. PubMed ID: 19344841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple combination antibiotic therapy for carbapenemase-producing Klebsiella pneumoniae: a systematic review.
    Jacobs DM; Safir MC; Huang D; Minhaj F; Parker A; Rao GG
    Ann Clin Microbiol Antimicrob; 2017 Nov; 16(1):76. PubMed ID: 29178957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae.
    Ni W; Li G; Zhao J; Cui J; Wang R; Gao Z; Liu Y
    Infect Dis (Lond); 2018 Jul; 50(7):507-513. PubMed ID: 29316830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta-analysis of RCTs.
    Shen F; Han Q; Xie D; Fang M; Zeng H; Deng Y
    Int J Infect Dis; 2015 Oct; 39():25-33. PubMed ID: 26283551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria.
    Heizmann WR; Löschmann PA; Eckmann C; von Eiff C; Bodmann KF; Petrik C
    Infection; 2015 Feb; 43(1):37-43. PubMed ID: 25367409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.